Survival among patients with systemic sclerosis‐associated pulmonary arterial hypertension in the Australian scleroderma cohort study
Abstract
Abstract Background and Aims Systemic sclerosis (scleroderma; SSc) patients can develop pulmonary arterial hypertension (PAH), which is a leading cause of death. We sought to evaluate severity, therapeutic strategy and survival of SSc‐PAH in the Australian Scleroderma Cohort Study (ASCS). Methods Among patients with 2013 American College of Rheumatology/European League Against Rheumatism‐defined SSc, PAH was defined as mean pulmonary artery pressure (mPAP) ≥20 mmHg, pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) >2 WU. Characteristics of those with and without PAH and those with incident PAH in 2014–2020 versus 2007–2013 were compared using descriptive statistics. Survival was evaluated using the Kaplan–Meier method and a multivariable Cox regression model. Results Among 1612 patients, 71 (4.4%) had incident PAH prior to censoring on 13 February 2024. Significantly more patients received PDE5i monotherapy in the first 12 months after PAH diagnosis in the later epoch (30 (63.8%) vs 6 (25.0%), P = 0.002). Dual therapy (any endothelin reception antagonist (ERA) and any PDE5i) was more common in the later epoch (26 (55.3%) vs 4 (16.7%), P = 0.002). Overall survival of those diagnosed with PAH between 2007 and 2013 was 91.67%, 87.50% and 56.88% at 1, 3 and 5 years. Overall survival of those diagnosed between 2014 and 2020 was 100.00%, 77.62% and 48.98% at 1, 3 and 5 years ( P = 0.414). Conclusions Despite increased use of dual therapy in the more recent epoch, we observed no significant improvement in overall survival in SSc‐PAH in our cohort. Our cohort's 1‐, 3‐ and 5‐year mortality is comparable to those reported for other contemporary SSc‐PAH cohorts.